Literature DB >> 9724020

Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.

H Lee1, I Struman, C Clapp, J Martial, R I Weiner.   

Abstract

The N-terminal fragment of PRL (16K PRL) is an antiangiogenic factor that, in vitro, inhibits several components of angiogenesis including basic fibroblast growth factor (bFGF)-induced cell division, migration, and organization of capillary endothelial cells. An essential step in the regulation of angiogenesis is the activation of urokinase (urokinase type plasminogen activator, uPA), which in turn activates a cascade of proteases that play essential roles in endothelial cell migration and tissue remodeling. Treatment of bovine capillary endothelial cells (BBEC) with 16K PRL inhibited bFGF-stimulated urokinase activity in BBEC as detected by plasminogen substrate gel assay. 16K PRL did not appear to be acting via an effect on uPA expression because no change in messenger RNA levels were observed. However, protein levels of plasminogen activator inhibitor-1 (PAI-1), a specific inhibitor of urokinase, were increased by 16K PRL independent of the action of bFGF. The 16K PRL-induced increase in PAI-1 protein levels appear to be the result of increased expression of the PAI-1 gene. Increased production of PAI-1 induced by 16K PRL results in the formation of inactive PAI-1/uPA complexes, consistent with the observed decrease in uPA activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724020     DOI: 10.1210/endo.139.9.6194

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.

Authors:  Ngoc-Quynh-Nhu Nguyen; Sebastien P Tabruyn; Laurence Lins; Michelle Lion; Anne M Cornet; Florence Lair; Francoise Rentier-Delrue; Robert Brasseur; Joseph A Martial; Ingrid Struman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

2.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

Authors:  I Struman; F Bentzien; H Lee; V Mainfroid; G D'Angelo; V Goffin; R I Weiner; J A Martial
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

3.  Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase.

Authors:  Albert S Chang; Ruriko Grant; Hirofumi Tomita; Hyung-Suk Kim; Oliver Smithies; Masao Kakoki
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

4.  Characterization of a bioactive 15 kDa fragment produced by proteolytic cleavage of chicken growth hormone.

Authors:  C Arámburo; M Carranza; M Reyes; M Luna; H Martinez-Coria; L Berúmen; C G Scanes
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

5.  Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control group.

Authors:  Uta Hönicke; Steffen Albrecht; Hagen Schrötter; Sabine Krug; Martin Kolditz; Eberhard Kuhlisch; Gert Höffken; Michael Halank
Journal:  Tex Heart Inst J       Date:  2012

Review 6.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

Review 7.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

8.  Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.

Authors:  Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado
Journal:  Clin Ophthalmol       Date:  2010-09-07

9.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

Authors:  Celina García; Jorge Aranda; Edith Arnold; Stéphanie Thébault; Yazmín Macotela; Fernando López-Casillas; Valentín Mendoza; Hugo Quiroz-Mercado; Hebert Luis Hernández-Montiel; Sue-Hwa Lin; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 10.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.